189 related articles for article (PubMed ID: 36302166)
1. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population.
Alduaij W; Collinge B; Ben-Neriah S; Jiang A; Hilton LK; Boyle M; Meissner B; Chong L; Miyata-Takata T; Slack GW; Farinha P; Craig JW; Lytle A; Savage KJ; Villa D; Gerrie AS; Freeman CL; Gascoyne RD; Connors JM; Morin RD; Sehn LH; Mungall AJ; Steidl C; Scott DW
Blood; 2023 May; 141(20):2493-2507. PubMed ID: 36302166
[TBL] [Abstract][Full Text] [Related]
2. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
[TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
4. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.
Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH
Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538
[TBL] [Abstract][Full Text] [Related]
5. High-grade B-cell lymphoma with
Scott DW; King RL; Staiger AM; Ben-Neriah S; Jiang A; Horn H; Mottok A; Farinha P; Slack GW; Ennishi D; Schmitz N; Pfreundschuh M; Nowakowski GS; Kahl BS; Connors JM; Gascoyne RD; Ott G; Macon WR; Rosenwald A
Blood; 2018 May; 131(18):2060-2064. PubMed ID: 29475959
[TBL] [Abstract][Full Text] [Related]
6. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
7. The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH.
Hilton LK; Tang J; Ben-Neriah S; Alcaide M; Jiang A; Grande BM; Rushton CK; Boyle M; Meissner B; Scott DW; Morin RD
Blood; 2019 Oct; 134(18):1528-1532. PubMed ID: 31527075
[TBL] [Abstract][Full Text] [Related]
8. Decreased CD11c-positive dendritic cells in the tumor microenvironment predict double-hit/triple-hit genotype and survival in diffuse large B-cell lymphoma.
Yuan CT; Chuang SS; Cheng PY; Chang K; Wang H; Tsai JH; Liau JY; Chou WC
J Pathol Clin Res; 2022 Sep; 8(5):436-447. PubMed ID: 35715938
[TBL] [Abstract][Full Text] [Related]
9. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
11. Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study.
Urata T; Naoi Y; Jiang A; Boyle M; Sunami K; Imai T; Nawa Y; Hiramatsu Y; Yamamoto K; Fujii S; Yoshida I; Yano T; Chijimatsu R; Murakami H; Ikeuchi K; Kobayashi H; Tani K; Ujiie H; Inoue H; Tomida S; Yamamoto A; Kondo T; Fujiwara H; Asada N; Nishimori H; Fujii K; Fujii N; Matsuoka KI; Sawada K; Momose S; Tamaru JI; Nishikori A; Sato Y; Yoshino T; Maeda Y; Scott DW; Ennishi D
Blood Adv; 2023 Dec; 7(24):7459-7470. PubMed ID: 37552496
[TBL] [Abstract][Full Text] [Related]
12. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: Biopsy analysis of 70 cases from the Slovak Lymphoma Registry.
Lešková K; Szépe P; Balhárek T; Barthová M; Janáková Ľ; Farkašová A; Plank L
Neoplasma; 2022 Jul; 69(4):957-964. PubMed ID: 35652622
[TBL] [Abstract][Full Text] [Related]
13. Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation.
Hori Y; Yamamoto H; Nozaki Y; Torisu T; Fujiwara M; Taguchi K; Nishiyama K; Nakamura S; Kitazono T; Oda Y
Hum Pathol; 2020 Feb; 96():67-78. PubMed ID: 31734190
[TBL] [Abstract][Full Text] [Related]
14. Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit.
Cucco F; Barrans S; Sha C; Clipson A; Crouch S; Dobson R; Chen Z; Thompson JS; Care MA; Cummin T; Caddy J; Liu H; Robinson A; Schuh A; Fitzgibbon J; Painter D; Smith A; Roman E; Tooze R; Burton C; Davies AJ; Westhead DR; Johnson PWM; Du MQ
Leukemia; 2020 May; 34(5):1329-1341. PubMed ID: 31844144
[TBL] [Abstract][Full Text] [Related]
15. Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
Deng M; Xu-Monette ZY; Pham LV; Wang X; Tzankov A; Fang X; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Hagemeister F; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Liu P; Young KH
Mol Cancer Res; 2021 Feb; 19(2):249-260. PubMed ID: 33154093
[TBL] [Abstract][Full Text] [Related]
16. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.
Hu S; Xu-Monette ZY; Tzankov A; Green T; Wu L; Balasubramanyam A; Liu WM; Visco C; Li Y; Miranda RN; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Slack GW; Gascoyne RD; Tu M; Variakojis D; Chen W; Go RS; Piris MA; Møller MB; Medeiros LJ; Young KH
Blood; 2013 May; 121(20):4021-31; quiz 4250. PubMed ID: 23449635
[TBL] [Abstract][Full Text] [Related]
17. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
Yan LX; Liu YH; Luo DL; Zhang F; Cheng Y; Luo XL; Xu J; Cheng J; Zhuang HG
PLoS One; 2014; 9(8):e104068. PubMed ID: 25090026
[TBL] [Abstract][Full Text] [Related]
18. Screening Strategy for Detecting Double-Hit Lymphoma in a Resource-Limited Setting.
Thirunavukkarasu B; Bal A; Prakash G; Malhotra P; Singh H; Das A
Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):49-55. PubMed ID: 34456240
[TBL] [Abstract][Full Text] [Related]
19. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
[TBL] [Abstract][Full Text] [Related]
20. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.
Deng M; Zhang M; Xu-Monette ZY; Pham LV; Tzankov A; Visco C; Fang X; Bhagat G; Zhu F; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Choi WWL; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; van Krieken JH; Piris MA; Winter JN; Hagemeister F; Alinari L; Li Y; Andreeff M; Xu B; Young KH
J Hematol Oncol; 2020 Nov; 13(1):148. PubMed ID: 33148342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
